Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Anavex Life Sciences Corp. (AVXL) Message Board

Two more anti-amyloid drugs flop. When will they g

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 1460
(Total Views: 365)
Posted On: 02/10/2020 9:28:02 AM
Avatar
Posted By: Drano
Re: fletch #992
Two more anti-amyloid drugs flop. When will they give up on this multi-billion research dollar wasting FAILED theory, and pay attention to alternative drugs, like AVXL's? Really, it's just so disgusting. They tried to make the data fit to show good results, and even with this outright cheating it failed.

https://endpts.com/focusing-on-genetically-de...ers-drugs/

Quote:
Neither Eli Lilly or Roche got any closer to proving their anti-amyloid therapies have a shred of value in the fight against Alzheimer’s as they disclosed topline results from a Phase II/III study involving patients with a rare inherited form of the disease.

Compared to the drugmakers’ previous failed trials, DIAN-TU was a small, customized effort that ran long. Investigators at Washington University in St Louis followed 194 participants — out of 490 randomized to receive Lilly’s solanezumab, Roche’s gantenerumab or placebo — for an average of 5 years and in some cases up to 7 years. They even tailor-made a composite endpoint comprising several cognitive assessments to suit this group of people with genetic mutations known to cause early onset Alzheimer’s, some of whom may not have had symptoms when they enrolled in the trial.

Even then, both solanezumab and gantenerumab failed the primary endpoint.



(2)
(0)




Anavex Life Sciences Corp. (AVXL) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us